Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of NASDAQ EVGN opened at $1.55 on Friday. The company has a 50 day simple moving average of $1.57 and a 200 day simple moving average of $2.37. The firm has a market cap of $8.31 million, a PE ratio of -0.35 and a beta of 1.29. Evogene has a 1 year low of $1.20 and a 1 year high of $10.40.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.40% of Evogene as of its most recent filing with the Securities and Exchange Commission. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.